Indication & Dosage |
| |
| |
| Oral |
| HRT |
| Adult:
In menopausal women: 10-20 mcg daily in conjunction with a progestogen in women with uterus. |
| |
| Oral |
| FEMALE HYPOGONADISM |
| Adult:
10-50 mcg daily in a cyclical regimen. |
| |
| Oral |
| PALLIATIVE TREATMENT OF BREAST CARCINOMA |
| Adult:
In postmenopausal women: 0.1-1 mg tid. |
| |
| Oral |
| PALLIATIVE TREATMENT OF PROSTATIC CARCINOMA |
| Adult:
0.15-3 mg daily. |
| |
| Oral |
| AS PART OF COMBINED ORAL CONTRACEPTIVE |
| Adult:
As the oestrogenic component of combined oral contraceptive: 20-40 mcg/day. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Asthma; epilepsy; migraine; DM; cardiac or renal dysfunction; hepatic disease; familial defects of lipoprotein metabolism. Increased risk of endometrial cancer in unopposed oestrogen therapy. Increased risk of gallbladder disease in women on postmenopausal oestrogens. Large doses may increase CV risk, BP, risk of thrombophlebitis and pulmonary embolism. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Oedema, hypertension; dizziness; headache; thromboembolism; cholestatic jaundice; nausea, vomiting; disturbance of menstrual cycle; fluid retention, discomfort in breast, wt gain/loss; increased appetite, increased tendency for vag candidiasis; mental depression; alteration in libido; rashes; alopoecia, hirsutism; gynaecomastia and impotence. |
| |
|
| Adverse Drug Reactions |
Endometrial cancer (prolonged use). |
| |
|
| Interactions |
Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs. CYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol. |
| |
|
